Odyssey Therapeutics Announces $279 Million Upsized IPO, Concurrent $25 Million Private Placement
Boston – May 7, 2026 – Cooley advised the underwriters of Odyssey Therapeutics, a clinical-stage biopharmaceutical company developing medicines that are designed to precisely target disease pathology, in connection with Odyssey’s $279 million upsized initial public offering (IPO) and concurrent $25 million private placement. Odyssey issued and sold 15,500,000 shares of its common stock priced at $18 per share, with a 30-day option for the underwriters to purchase 2,325,000 million additional shares. Odyssey’s common stock will begin trading on Nasdaq Capital Market on May 8, 2026, under the ticker symbol ODTX.
Additionally, Odyssey announced a concurrent sale of 1,388,889 shares of common stock to an affiliate of TPG Life Sciences Innovations, at the IPO price of $18 per share, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended.
J.P. Morgan, TD Cowen and Cantor are acting as joint book-running managers for the IPO. Wedbush PacGrow and Oppenheimer & Co. are acting as co-lead managers for the IPO.
Lawyers Eric Blanchard, Evan Leitner, Richard Segal, Div Gupta, Trevor Bossi, Brenna McGuire, Chelsea Braun and Amelia Griffiths led the Cooley team advising the underwriters.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.